Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 24, 2026, 4:27 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Height Clear all
Terminated Phase 4 Interventional Results available

Effect of Topical Botulinum Toxin Eyedrop on Palpebral Fissure

NCT06080438
View directory record Official record
Conditions
Tears; Excess, Eyelid Spasm
Interventions
Botulinum toxin
Drug
Lead sponsor
University of Miami
Other
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Dec 4, 2024 · Synced Jul 24, 2026, 4:27 AM EDT
Completed Phase 3 Interventional Results available

Genotropin Study Assessing Use of Injection Pen

NCT00965484
View directory record Official record
Conditions
Growth Hormone Deficiency, Idiopathic Short Stature
Interventions
New Genotropin Pen
Device
Lead sponsor
Pfizer
Industry
Eligibility
8 Years to 18 Years
Enrollment
136 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
25
States / cities
Los Angeles, California • San Diego, California • Greenwood Village, Colorado + 18 more
Source: ClinicalTrials.gov public record
Updated Jan 27, 2011 · Synced Jul 24, 2026, 4:27 AM EDT
Completed Phase 3 Interventional

The Effect of Androgen and Growth Hormone on Height and Learning in Girls With Turner Syndrome

NCT00029159
View directory record Official record
Conditions
Turner Syndrome
Interventions
estrogen, androgen, placebo
Drug · Other
Lead sponsor
Thomas Jefferson University
Other
Eligibility
10 Years to 14 Years · Female only
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1992 – 2012
U.S. locations
2
States / cities
Bethesda, Maryland • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 4, 2012 · Synced Jul 24, 2026, 4:27 AM EDT
Completed Phase 2 Interventional Results available

Phase 2 Study of LUM-201 in Children Who Have Previously Completed the LUM-201-01 Trial (OraGrowtH213)

NCT05250063
View directory record Official record
Conditions
Growth Hormone Deficiency
Interventions
LUM-201
Drug
Lead sponsor
Lumos Pharma
Industry
Eligibility
3 Years to 13 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
7
States / cities
San Diego, California • Washington D.C., District of Columbia • Indianapolis, Indiana + 4 more
Source: ClinicalTrials.gov public record
Updated May 14, 2026 · Synced Jul 24, 2026, 4:27 AM EDT
Active, not recruiting No phase listed Observational

The Impact of Tibial Tubercle-trochlear Groove Distance and Patellar Height on the Outcome of Isolated Medial Patellofemoral Ligament Reconstruction

NCT03076008
View directory record Official record
Conditions
Patellar Dislocation
Interventions
Observational
Other
Lead sponsor
University of Minnesota
Other
Eligibility
13 Years to 90 Years
Enrollment
201 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2026
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Jul 13, 2026 · Synced Jul 24, 2026, 4:27 AM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers

Evaluating the Effects of an Oral Protein Supplement on Children's Growth Patterns

NCT06329388
View directory record Official record
Conditions
Growth Disorders, Dietary Exposure, Child Development, Bone Development Abnormal, Body Weight, Child Malnutrition
Interventions
TruHeight Growth Protein Shake
Dietary Supplement
Lead sponsor
TruHeight Vitamins
Industry
Eligibility
4 Years to 17 Years
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Mar 25, 2024 · Synced Jul 24, 2026, 4:27 AM EDT
Not listed Not applicable Interventional Accepts healthy volunteers

D-Cycloserine-Enhancer of One-Session Treatment for Phobia of Heights

NCT01037101
View directory record Official record
Conditions
Height Phobia
Interventions
In Vivo Exposure Therapy, Virtual Reality Exposure Therapy, D-Cycloserine, Placebo
Behavioral · Drug
Lead sponsor
CAMC Health System
Other
Eligibility
18 Years to 65 Years
Enrollment
80 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2014
U.S. locations
1
States / cities
Charleston, West Virginia
Source: ClinicalTrials.gov public record
Updated Oct 13, 2013 · Synced Jul 24, 2026, 4:27 AM EDT
Recruiting Not applicable Interventional

The Effects of AFO Heel Height and Stiffness on Gait

NCT04800484
View directory record Official record
Conditions
Musculoskeletal Injury, Musculoskeletal Diseases, Peripheral Nervous System Diseases
Interventions
Tall Soft, Tall Firm, Short Soft, Short Firm
Device
Lead sponsor
University of Iowa
Other
Eligibility
18 Years to 70 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2027
U.S. locations
1
States / cities
Iowa City, Iowa
Source: ClinicalTrials.gov public record
Updated Dec 30, 2025 · Synced Jul 24, 2026, 4:27 AM EDT
Recruiting Not applicable Interventional

How a Mediterranean Diet With Potatoes Impacts Heart and Metabolic Health in Adults With Pre-Diabetes

NCT06817252
View directory record Official record
Conditions
Prediabetes, Lipid Profile, Hypertension, Glycemic Control, Arterial Stiffness, Blood Pressure, Inflammation Biomarkers, Dietary Quality, Body Composition Measurement, Waist Circumference, Anthropometrics: Height and Weight
Interventions
Mediterranean Diet Nutrition Education, Mediterranean Diet Nutrition Education with Baked White Potato
Behavioral
Lead sponsor
University of Nevada, Las Vegas
Other
Eligibility
45 Years to 80 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
2
States / cities
Las Vegas, Nevada
Source: ClinicalTrials.gov public record
Updated Nov 19, 2025 · Synced Jul 24, 2026, 4:27 AM EDT
Recruiting Phase 2 Interventional

Vosoritide for Short Stature in Turner Syndrome

NCT05849389
View directory record Official record
Conditions
Turner Syndrome, Short Stature
Interventions
Vosoritide
Drug
Lead sponsor
Roopa Kanakatti Shankar, MBBS, MS
Other
Eligibility
3 Years to 11 Years · Female only
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Jun 23, 2024 · Synced Jul 24, 2026, 4:27 AM EDT
Not yet recruiting Phase 2 Interventional

Bempedoic Acid Therapy for Polycystic Kidney Disease

NCT07282821
View directory record Official record
Conditions
ADPKD (Autosomal Dominant Polycystic Kidney Disease)
Interventions
Bempedoic Acid 180 MG Oral Tablet, Placebo Capsule(s)
Drug
Lead sponsor
Kenneth Hallows
Other
Eligibility
18 Years to 60 Years
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
3
States / cities
Baltimore, Maryland • Boston, Massachusetts • Burlington, Vermont
Source: ClinicalTrials.gov public record
Updated Jul 22, 2026 · Synced Jul 24, 2026, 4:27 AM EDT
Completed Phase 2 Interventional

Study of Luteinizing Hormone-Releasing Hormone Analog (LHRHa) in Pubertal Patients With Extreme Short Stature

NCT00001190
View directory record Official record
Conditions
Dwarfism, Growth Disorder
Interventions
Deslorelin
Drug
Lead sponsor
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
NIH
Eligibility
Not listed
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1983 – 2001
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 3, 2008 · Synced Jul 24, 2026, 4:27 AM EDT
Completed Phase 2 Interventional

Effect of Biosynthetic Growth Hormone and/or Ethinyl Estradiol on Adult Height in Patients With Turner Syndrome

NCT00001221
View directory record Official record
Conditions
Gonadal Dysgenesis, Turner's Syndrome
Interventions
Growth Hormone (Humatrope)
Drug
Lead sponsor
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
NIH
Eligibility
Female only
Enrollment
160 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1987 – 2003
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 3, 2008 · Synced Jul 24, 2026, 4:27 AM EDT
Active, not recruiting Phase 3 Interventional Results available

A Research Study Looking at How Safe Somapacitan is and How Well it Works in Children Who Need Help to Grow - REAL 9

NCT05723835
View directory record Official record
Conditions
SGA, Turner Syndrome, Noonan Syndrome, ISS
Interventions
Somapacitan
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
10 Years to 18 Years
Enrollment
47 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
6
States / cities
Birmingham, Alabama • Sacramento, California • Centennial, Colorado + 3 more
Source: ClinicalTrials.gov public record
Updated Jul 8, 2026 · Synced Jul 24, 2026, 4:27 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Virtual Reality Intervention for Fear of Heights

NCT06468878
View directory record Official record
Conditions
Acrophobia
Interventions
Exposure Intervention Plus Music Induction, Exposure Intervention With No Music Induction
Behavioral
Lead sponsor
Boston University Charles River Campus
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 24, 2026 · Synced Jul 24, 2026, 4:27 AM EDT
Terminated No phase listed Observational Accepts healthy volunteers

Genetic Causes of Growth Disorders

NCT02311322
View directory record Official record
Conditions
Short Stature, Growth Disorder, Syndromic Growth Disorder, Tall Stature
Interventions
Not listed
Lead sponsor
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
NIH
Eligibility
Not listed
Enrollment
334 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2023
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 15, 2023 · Synced Jul 24, 2026, 4:27 AM EDT
Completed Phase 2Phase 3 Interventional Results available

Long-Term Treatment With rhIGF-1 in GHIS

NCT00571727
View directory record Official record
Conditions
Growth Hormone Insensitivity Syndrome
Interventions
mecasermin
Drug
Lead sponsor
Ipsen
Industry
Eligibility
2 Years to 21 Years
Enrollment
92 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1991 – 2011
U.S. locations
1
States / cities
Brisbane, California
Source: ClinicalTrials.gov public record
Updated Jul 5, 2023 · Synced Jul 24, 2026, 4:27 AM EDT
Completed Phase 3 Interventional

A Study to Evaluate the Efficacy and Safety of Infigratinib in Children and Adolescents With Achondroplasia

NCT06164951
View directory record Official record
Conditions
Achondroplasia
Interventions
Infigratinib 0.25 mg/kg/day, Placebo Comparator 0.25 mg/kg/day
Drug
Lead sponsor
QED Therapeutics, a BridgeBio company
Industry
Eligibility
3 Years to 17 Years
Enrollment
114 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
7
States / cities
San Francisco, California • Aurora, Colorado • Baltimore, Maryland + 4 more
Source: ClinicalTrials.gov public record
Updated Mar 16, 2026 · Synced Jul 24, 2026, 4:27 AM EDT
Not listed No phase listed Observational

Testing the Developmental Origins Hypothesis

NCT01545492
View directory record Official record
Conditions
Diabetes, Stroke, Obesity
Interventions
Not listed
Lead sponsor
Children's & Women's Health Centre of British Columbia
Other
Eligibility
Not listed
Enrollment
626 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2019
U.S. locations
4
States / cities
New Haven, Connecticut • Louisville, Kentucky • Camden, New Jersey + 1 more
Source: ClinicalTrials.gov public record
Updated Mar 5, 2012 · Synced Jul 24, 2026, 4:27 AM EDT
Terminated Phase 1Phase 2 Interventional Accepts healthy volunteers Results available

Free Fatty Acids, Body Weight, and Growth Hormones Secretion in Children

NCT01237041
View directory record Official record
Conditions
Obesity, Short Stature, Growth Hormone Deficiency
Interventions
Niacin First, Placebo First, Dose-Establishing Study 1 Niacin 250mg, Dose-Establishing Study 1 Niacin 500mg, Dose-Establishing Study 2 Niacin 500mg
Drug
Lead sponsor
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
NIH
Eligibility
7 Years to 14 Years
Enrollment
37 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2017
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 16, 2018 · Synced Jul 24, 2026, 4:27 AM EDT
Completed Phase 2 Interventional

Nutrients and Hormones: Effects in Boys With Disordered Growth

NCT00139451
View directory record Official record
Conditions
Constitutional Growth Delay, Nutrition Disorders, Growth Disorders
Interventions
Pediasure, GH
Drug
Lead sponsor
Nemours Children's Clinic
Other
Eligibility
7 Years to 10 Years · Male only
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2010
U.S. locations
1
States / cities
Jacksonville, Florida
Source: ClinicalTrials.gov public record
Updated Oct 11, 2011 · Synced Jul 24, 2026, 4:27 AM EDT
Completed No phase listed Observational

Study of Skeletal Disorders and Short Stature

NCT00001754
View directory record Official record
Conditions
Developmental Bone Disease, Dwarfism, Skeletal Dysplasias
Interventions
Not listed
Lead sponsor
National Human Genome Research Institute (NHGRI)
NIH
Eligibility
Not listed
Enrollment
600 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1998 – 2001
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 3, 2008 · Synced Jul 24, 2026, 4:27 AM EDT
Completed Phase 1 Interventional

Pappalysin 2 (PAPP-A2) Enzyme Replacement

NCT02412943
View directory record Official record
Conditions
Short Stature, Idiopathic
Interventions
Fresh Frozen Plasma
Other
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
18 Years and older · Female only
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated May 27, 2015 · Synced Jul 24, 2026, 4:27 AM EDT
Recruiting No phase listed Observational

Prospective Clinical Assessment Study in Children With Hypochondroplasia

NCT06410976
View directory record Official record
Conditions
Hypochondroplasia
Interventions
Not listed
Lead sponsor
QED Therapeutics, a BridgeBio company
Industry
Eligibility
30 Months to 16 Years
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
8
States / cities
Oakland, California • Aurora, Colorado • Washington D.C., District of Columbia + 5 more
Source: ClinicalTrials.gov public record
Updated Jul 15, 2026 · Synced Jul 24, 2026, 4:27 AM EDT